AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16162694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 1280 microg bid (CIC 1280)
Number of subjects: 60
Study 16162694 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 440 microg bid (FP 880)
Number of subjects: 60
Study 16162694 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 880 microg bid (FP 1760)
Number of subjects: 60
Study 16162694 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 60
Study 12867607 — intervention group
Group type: EXPERIMENTAL
Intervention: Impermeable bedding covers
Number of subjects: 279
Study 12867607 — intervention group
Group type: COMPARATOR
Intervention: Non-impermeable bedding covers (control)
Number of subjects: 279
Study 10381042 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX 15-20 mg/week
Number of subjects: 41
Study 10381042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 8689188 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 59
Study 8689188 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux surgery
Number of subjects: 59
Study 1568727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperlipidemia associated with primary biliary cirrhosis
Number of subjects: 312
Study 1568727 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed serum lipid profiles in 50 consecutive PBC patients
Number of subjects: 312
Study 6131683 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 1 mg kg‐1 followed by Org NC 45 40 micrograms kg‐1 5 min after recovery (group I)
Number of subjects: 25
Study 6131683 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 1 mg kg‐1 followed by Org NC 45 40 micrograms kg‐1 15 min after recovery (group II)
Number of subjects: 25
Study 6131683 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 1 mg kg‐1 followed by Org NC 45 40 micrograms kg‐1 30 min after recovery (group III)
Number of subjects: 25
Study 6131683 — intervention group
Group type: COMPARATOR
Intervention: Org NC 45 40 micrograms kg‐1 (group IV)
Number of subjects: 25
Study 6131683 — intervention group
Group type: COMPARATOR
Intervention: Org NC 45 80 micrograms kg‐1 (group V)
Number of subjects: 25
Study 6131683 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 1 mg kg‐1 followed by Org NC 45 (groups I, II, III)
Number of subjects: 25
Study 31719135 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with ischemic stroke
Number of subjects: 19652
Study 28700844 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 731
Study 28700844 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 731
Study 25594377 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line (OL) condition with visual feedback during movement production
Number of subjects: 0
Study 25594377 — intervention group
Group type: COMPARATOR
Intervention: Pre-planned (PP) condition without visual feedback during movement production
Number of subjects: 0
Study 23332657 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐to‐1 pelvic floor muscle training (PFMT) and a self‐instruction manual (SIM)
Number of subjects: 140
Study 23332657 — intervention group
Group type: COMPARATOR
Intervention: Self‐instruction manual (SIM) alone
Number of subjects: 140
Study 21428467 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride and IL-2 as maintenance therapy
Number of subjects: 0
Study 21428467 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 21428467 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride and IL-2 therapy
Number of subjects: 0
Study 19207300 — intervention group
Group type: COMPARATOR
Intervention: Passive forearm motion sensitivity in children
Number of subjects: 30
Study 19207300 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive forearm motion sensitivity in adults
Number of subjects: 30
Study 16884465 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal group (1 ml.kg(‐1) 0.25% bupivacaine)
Number of subjects: 47
Study 16884465 — intervention group
Group type: COMPARATOR
Intervention: Control group (no caudal)
Number of subjects: 47
Study 12527981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 70% FCC cadence
Number of subjects: 10
Study 12527981 — intervention group
Group type: COMPARATOR
Intervention: Cycling at 85%, 100%, 115%, and 130% FCC cadences
Number of subjects: 10
Study 12527981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 60%, 80%, and 100% maximal aerobic power
Number of subjects: 10
Study 10615738 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone only (50 mg once daily)
Number of subjects: 100
Study 10615738 — intervention group
Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 100
Study 10615738 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with nicotine patches (50 mg once daily + 21 mg/24-hour for first 8 weeks, 14 mg/24-hour for last 4 weeks)
Number of subjects: 100
Study 10615738 — intervention group
Group type: COMPARATOR
Intervention: Placebo with nicotine patches
Number of subjects: 100
Study 9008982 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand's Essence of Chicken (BEC)
Number of subjects: 20
Study 9008982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1523998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirarubicin (THP) instillation at a dose of 500 micrograms/ml, 3 times per week for 3 weeks
Number of subjects: 63
Study 1523998 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin (ADM) instillation at a dose of 500 micrograms/ml, 3 times per week for 3 weeks
Number of subjects: 63
Study 6497936 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg tamoxifen daily for 2 months
Number of subjects: 23
Study 6497936 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched healthy females)
Number of subjects: 23
Study 30963353 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-loaded liposomal chitosan gel
Number of subjects: 0
Study 30963353 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29735461 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study 29735461 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 0
Study 27036515 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training (VRT)
Number of subjects: 76
Study 27036515 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional therapy)
Number of subjects: 76
Study 24732026 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI + LLP
Number of subjects: 51
Study 24732026 — intervention group
Group type: EXPERIMENTAL
Intervention: AA + LLP
Number of subjects: 51
Study 24732026 — intervention group
Group type: EXPERIMENTAL
Intervention: LLP
Number of subjects: 51
Study 24732026 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI
Number of subjects: 51
Study 24732026 — intervention group
Group type: COMPARATOR
Intervention: HE
Number of subjects: 51
Study 24732026 — intervention group
Group type: COMPARATOR
Intervention: AA + HE
Number of subjects: 51
Study 22115712 — intervention group
Group type: EXPERIMENTAL
Intervention: EGP‐437 (dexamethasone phosphate) via iontophoresis at 1.6 mA‐min
Number of subjects: 40
Study 22115712 — intervention group
Group type: EXPERIMENTAL
Intervention: EGP‐437 (dexamethasone phosphate) via iontophoresis
Number of subjects: 40
Study 20530395 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated intervention group
Number of subjects: 36
Study 20530395 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed intervention group
Number of subjects: 36
Study 20530395 — intervention group
Group type: COMPARATOR
Intervention: Control group (self-directed)
Number of subjects: 36
Study 18083469 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 mcg/kg IV for 10 minutes followed by 0.3 mcg/kg IV for 50 minutes)
Number of subjects: 30
Study 18083469 — intervention group
Group type: COMPARATOR
Intervention: Propacetamol (2 g IV for 10 minutes)
Number of subjects: 30
Study 16026220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) with adjunctive parent component
Number of subjects: 0
Study 16026220 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) without parent component
Number of subjects: 0
Study 11925385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) treatment in patients with elevated progesterone levels
Number of subjects: 0
Study 11925385 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH administration during suppression of endogenous gonadotrophin secretion
Number of subjects: 0
Study 11925385 — intervention group
Group type: COMPARATOR
Intervention: Ethinyl estradiol intake
Number of subjects: 0
Study 10215217 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term implantation of left ventricular assist devices
Number of subjects: 0
Study 10215217 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical management
Number of subjects: 0
Study 8691565 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (200 micrograms/m2 iv) administration starting 24 hrs after chemotherapy (Group A)
Number of subjects: 57
Study 8691565 — intervention group
Group type: COMPARATOR
Intervention: G-CSF (200 micrograms/m2 iv) administration after a febrile episode of 38 degrees C with neutropenia (Group B)
Number of subjects: 57
Study 8691565 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (Group A)
Number of subjects: 57
Study 2178487 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg triazolam
Number of subjects: 65
Study 2178487 — intervention group
Group type: COMPARATOR
Intervention: 2 mg flunitrazepam
Number of subjects: 65
Study 420326 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture treatment
Number of subjects: 3
Study 420326 — intervention group
Group type: COMPARATOR
Intervention: Pseudo-acupuncture (random needling)
Number of subjects: 3
Study 420326 — intervention group
Group type: COMPARATOR
Intervention: No treatment control periods
Number of subjects: 3
Study 30458636 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional phototherapy
Number of subjects: 120
Study 30458636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive phototherapy
Number of subjects: 120
Study 30458636 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light‐emitting diodes (LED) phototherapy
Number of subjects: 120
Study 30458636 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 26063788 — intervention group
Group type: EXPERIMENTAL
Intervention: Your Moment of Truth (YMOT) intervention, 6 sessions of 2 hours each
Number of subjects: 1543
Study 26063788 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 1543
Study 26063788 — intervention group
Group type: EXPERIMENTAL
Intervention: Your Moment of Truth (YMOT) intervention
Number of subjects: 1543
Study 25795947 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WP)
Number of subjects: 68
Study 25795947 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (SP)
Number of subjects: 68
Study 24138994 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (20‐min group session, physical poses, once per week for 12 weeks)
Number of subjects: 92
Study 24138994 — intervention group
Group type: COMPARATOR
Intervention: Social support (leaderless discussion group, same schedule as yoga)
Number of subjects: 92
Study 24138994 — intervention group
Group type: COMPARATOR
Intervention: Yoga and Social Support (both groups)
Number of subjects: 92
Study 20690869 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring stretching in sitting (SI)
Number of subjects: 36
Study 20690869 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring stretching in standing (ST)
Number of subjects: 36
Study 20690869 — intervention group
Group type: COMPARATOR
Intervention: No stretching (control)
Number of subjects: 36
Study 18976268 — intervention group
Group type: EXPERIMENTAL
Intervention: hard occlusal splint (HS)
Number of subjects: 42
Study 18976268 — intervention group
Group type: EXPERIMENTAL
Intervention: soft occlusal splint (SS)
Number of subjects: 42
Study 18976268 — intervention group
Group type: EXPERIMENTAL
Intervention: non-occluding occlusal splint (NS)
Number of subjects: 42
Study 16397167 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins (folic acid, vitamin B12, and B6)
Number of subjects: 443
Study 16397167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 12375220 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 55
Study 12375220 — intervention group
Group type: COMPARATOR
Intervention: Control (No Atropine)
Number of subjects: 55
Study 9951672 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE with intraocular lens implantation
Number of subjects: 110
Study 7489796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold dry air during exercise
Number of subjects: 100
Study 7489796 — intervention group
Group type: COMPARATOR
Intervention: Room air during exercise
Number of subjects: 100
Study 2107608 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard PN solution
Number of subjects: 7
Study 2107608 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% dextrose water (D10W)
Number of subjects: 7
Study 2107608 — intervention group
Group type: COMPARATOR
Intervention: Control (meal)
Number of subjects: 7
Study 109382 — intervention group
Group type: EXPERIMENTAL
Intervention: Butalamine hydrochloride tablets (80 mg each), daily dose of 3 x 2 tablets
Number of subjects: 113
Study 109382 — intervention group
Group type: EXPERIMENTAL
Intervention: Butalamine hydrochloride tablets (80 mg each), daily dose of 3 x 1 tablet
Number of subjects: 113
Study 29905879 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based psychosocial interventions
Number of subjects: 0
Study 29905879 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 27273839 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warnings on cigarette packs
Number of subjects: 2149
Study 27273839 — intervention group
Group type: COMPARATOR
Intervention: Text-only warnings on cigarette packs
Number of subjects: 2149
Study 26181221 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized sedation
Number of subjects: 289
Study 26181221 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized sedation plus daily interruption
Number of subjects: 289
Study 26181221 — intervention group
Group type: COMPARATOR
Intervention: No ICU recall
Number of subjects: 289
Study 26181221 — intervention group
Group type: EXPERIMENTAL
Intervention: Delusional memories
Number of subjects: 289
Study 21951313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection (IVBI)
Number of subjects: 50
Study 21951313 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal ranibizumab injection (IVRI)
Number of subjects: 50
Study 21951313 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IVBI and IVRI
Number of subjects: 50
Study 21903553 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine
Number of subjects: 20
Study 21903553 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy without chlorhexidine
Number of subjects: 20
Study 17486573 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition (intoxication)
Number of subjects: 74
Study 17486573 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 74
Study 17486573 — intervention group
Group type: EXPERIMENTAL
Intervention: High salience cue
Number of subjects: 74
Study 17486573 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salience cue
Number of subjects: 74
Study 16639071 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin incision omission PEG (IOPEG)
Number of subjects: 50
Study 16639071 — intervention group
Group type: COMPARATOR
Intervention: Standard PEG (SPEG)
Number of subjects: 50
Study 14534519 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (2 mg estradiol valerate and 250 microg levonorgestrel)
Number of subjects: 12
Study 14534519 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (30 microg ethinyl estradiol and 150 microg desogestrel)
Number of subjects: 12
Study 14534519 — intervention group
Group type: COMPARATOR
Intervention: Control phase (150 mg bupropion without pretreatment)
Number of subjects: 12
Study 10591840 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent physical activity, Lean mass, African-American race
Number of subjects: 393
Study 10591840 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein, calcium, recent physical activity
Number of subjects: 393
Study 10591840 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean body mass, premenopausal status
Number of subjects: 393
Study 10591840 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean body mass, physical activity, African-American race, body mass index
Number of subjects: 393
Study 10591840 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 393
Study 7784119 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX) urinary tract prophylaxis
Number of subjects: 43
Study 7784119 — intervention group
Group type: COMPARATOR
Intervention: Control group (discontinuing antibiotic prophylaxis)
Number of subjects: 43
Study 2352049 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle Ear Implant (MEI)
Number of subjects: 10
Study 2352049 — intervention group
Group type: COMPARATOR
Intervention: Hearing Aid (HA)
Number of subjects: 10
Study 2352049 — intervention group
Group type: COMPARATOR
Intervention: Middle Ear Implant (MEI) and Hearing Aid (HA)
Number of subjects: 10
Study 345380 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbuterol
Number of subjects: 20
Study 345380 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 20
Study 30021451 — intervention group
Group type: EXPERIMENTAL
Intervention: Process incentives for attending weekly Diabetes Prevention Program sessions
Number of subjects: 703
Study 30021451 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome incentives for achieving weekly weight loss goals
Number of subjects: 703
Study 30021451 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined process and outcome incentives
Number of subjects: 703
Study 30021451 — intervention group
Group type: COMPARATOR
Intervention: Control (no incentives)
Number of subjects: 703
Study 28542112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation combined with conventional physical therapy (40 min + 20 min for 3 weeks, then 60 min conventional therapy for 3 weeks)
Number of subjects: 28
Study 28542112 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (60 min for 6 weeks)
Number of subjects: 28
Study 27037872 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized home-based exercise (HE)
Number of subjects: 210
Study 27037872 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based exercise (GE)
Number of subjects: 210
Study 27037872 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) receiving usual community care
Number of subjects: 210
Study 23494779 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia (MMA)
Number of subjects: 54
Study 23494779 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 21846286 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite health promotion intervention
Number of subjects: 0
Study 19594199 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 25 mg once daily
Number of subjects: 0
Study 19594199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17893252 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin-14 (SS-14) 2.0 microg/kg per h
Number of subjects: 9
Study 17893252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortistatin-17 (CST-17) 2.0 microg/kg per h
Number of subjects: 9
Study 17893252 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 9
Study 15717651 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP test (0.3 UI iv bolus)
Number of subjects: 23
Study 15717651 — intervention group
Group type: EXPERIMENTAL
Intervention: APZ/AVP test (0.5 mg at midnight and 0.5 mg 90 min before the test)
Number of subjects: 23
Study 15717651 — intervention group
Group type: COMPARATOR
Intervention: APZ (0.5 mg at midnight and 0.5 mg 90 min before the test)
Number of subjects: 23
Study 12097783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day
Number of subjects: 501
Study 12097783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 90 mg twice a week
Number of subjects: 501
Study 12097783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study 9817625 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg/day)
Number of subjects: 308
Study 9817625 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20-60 mg/day)
Number of subjects: 308
Study 9817625 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline or Citalopram
Number of subjects: 308
Study 7703061 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular occlusion of side branches (EAI)
Number of subjects: 64
Study 7703061 — intervention group
Group type: COMPARATOR
Intervention: Conventional open technique (CI)
Number of subjects: 64
Study 31906903 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-integrated cognitive behavior therapy (MiCBT)
Number of subjects: 120
Study 31906903 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (wait-list control)
Number of subjects: 120
Study 29037845 — intervention group
Group type: EXPERIMENTAL
Intervention: Model osteoarthritis consultation
Number of subjects: 525
Study 29037845 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 525
Study 28029669 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (group 2)
Number of subjects: 60
Study 28029669 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (group 1)
Number of subjects: 60
Study 25582305 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 40
Study 25582305 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 40